Analyst firms · Argus Research · BIIB
Argus Research BIIB price target and rating history
Biogen Inc. (BIIB) · Health Care
Argus Research rates Biogen Inc. (BIIB) Buy with a $280 price target, as of its latest action on Oct 29, 2026. It has published 3 rating actions on BIIB since October 2022, including 2 upgrades and 1 downgrade. Across 10 firms with a BIIB price target in the last 12 months, the median target is $231.50. Argus Research's $280 is 21% above that.
- Current rating
- Buy
- Price target
- $280
- Median target, all firms
- $231.50
- Actions on BIIB
- 3
Argus Research price target on BIIB
Every Argus Research rating on BIIB
- Oct 29, 2026
- Apr 4, 2025
- Oct 7, 2022
How other firms rate BIIB
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Argus Research | Buy | $280 | Oct 29, 2026 |
| Wolfe Research | Outperform | $300 | Aug 13, 2026 |
| Truist Securities | Buy | $235 | Jul 13, 2026 |
| Needham | Buy | $255 | Jun 8, 2026 |
| Evercore ISI | Outperform | May 15, 2026 | |
| UBS | Buy | $225 | Apr 22, 2026 |
| Wells Fargo | Overweight | $250 | Apr 20, 2026 |
| Piper Sandler | Overweight | $214 | Apr 14, 2026 |
| Barclays | Equal Weight | $185 | Feb 20, 2026 |
| H.C. Wainwright | Buy | $228 | Feb 9, 2026 |
| HSBC | Reduce | $143 | Dec 10, 2025 |
Questions about Argus Research and BIIB
- What is Argus Research's price target for BIIB?
- Argus Research's latest stated price target for Biogen Inc. (BIIB) is $280, from its action on Oct 29, 2026.
- What is Argus Research's rating on BIIB?
- Argus Research rates BIIB Buy, a bullish rating, as of Oct 29, 2026.
- When did Argus Research last change its view on BIIB?
- On Oct 29, 2026, Argus Research upgrades to Buy from Hold, price target $280.
- How does Argus Research's BIIB target compare with other analysts?
- Across 10 firms with a BIIB price target in the last 12 months, the median target is $231.50. Argus Research's $280 is 21% above that.
More BIIB rating histories
- Wolfe Research3
- Needham9
- UBS5
- Wells Fargo5
- Piper Sandler4
- Barclays4
- HSBC3
- Stifel5
- Jefferies3
- BMO Capital Markets4
- BofA Securities3
- Morgan Stanley8
- Raymond James3
- Robert W. Baird3
- Mizuho3
- RBC Capital Markets7
- Oppenheimer3
All Argus Research ratingsBIIB news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.